Q-omics provides the consensus-scored ALG2 profile across patient tissues and cancer cell-line models. ALG2 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ALG2 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ALG2 protein abundance shows 26,494 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where ALG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ALG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ALG2 survival associations across molecular data types. ALG2 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ALG2 RNA expression–survival associations across cancer types. High ALG2 expression shows unfavorable associations in HNSC, UVM, ACC and LGG, but favorable associations in KIRC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ALG2 RNA expression.
This table summarizes ALG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ALG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ALG2 shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, STAD, LIHC and BRCA. The HNSC box plot shows higher ALG2 RNA expression in tumor versus normal tissue (log2 FC = +0.823, t-test p < 0.001).
This table shows molecular features associated with ALG2 in patient tissues and cancer cell lines. In patient samples, ALG2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ALG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BONE and LUNG_NSCLC_LUAD.
